JP2019500345A - 肝臓病の処置のための組成物および方法 - Google Patents
肝臓病の処置のための組成物および方法 Download PDFInfo
- Publication number
- JP2019500345A JP2019500345A JP2018529229A JP2018529229A JP2019500345A JP 2019500345 A JP2019500345 A JP 2019500345A JP 2018529229 A JP2018529229 A JP 2018529229A JP 2018529229 A JP2018529229 A JP 2018529229A JP 2019500345 A JP2019500345 A JP 2019500345A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- nucleobases
- intron
- target protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 106
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 208000019423 liver disease Diseases 0.000 title claims abstract description 53
- 238000011282 treatment Methods 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 317
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 228
- 230000014509 gene expression Effects 0.000 claims abstract description 55
- 230000001965 increasing effect Effects 0.000 claims abstract description 43
- 230000002950 deficient Effects 0.000 claims abstract description 26
- 108020004999 messenger RNA Proteins 0.000 claims description 207
- 239000002243 precursor Substances 0.000 claims description 150
- 230000000717 retained effect Effects 0.000 claims description 150
- 230000000692 anti-sense effect Effects 0.000 claims description 108
- 102100024824 3 beta-hydroxysteroid dehydrogenase type 7 Human genes 0.000 claims description 93
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims description 92
- 101000760747 Homo sapiens Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 claims description 91
- 102100024591 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims description 91
- 102100034389 Low density lipoprotein receptor adapter protein 1 Human genes 0.000 claims description 86
- 101000761592 Homo sapiens 3 beta-hydroxysteroid dehydrogenase type 7 Proteins 0.000 claims description 85
- 102100022932 Nuclear receptor coactivator 5 Human genes 0.000 claims description 83
- 102100023167 Argininosuccinate lyase Human genes 0.000 claims description 82
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 claims description 82
- 102100039338 Aminomethyltransferase, mitochondrial Human genes 0.000 claims description 81
- 102000004889 Interleukin-6 Human genes 0.000 claims description 81
- 108090001005 Interleukin-6 Proteins 0.000 claims description 81
- 102100025392 Isovaleryl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims description 81
- 102100030396 Protein O-glucosyltransferase 1 Human genes 0.000 claims description 81
- 102100036284 Hepcidin Human genes 0.000 claims description 80
- 101001021253 Homo sapiens Hepcidin Proteins 0.000 claims description 80
- 102100035401 Ceramide synthase 2 Human genes 0.000 claims description 79
- 102100034391 Porphobilinogen deaminase Human genes 0.000 claims description 78
- 108020001991 Protoporphyrinogen Oxidase Proteins 0.000 claims description 78
- 102000005135 Protoporphyrinogen oxidase Human genes 0.000 claims description 78
- 230000007812 deficiency Effects 0.000 claims description 78
- 101150025804 Asl gene Proteins 0.000 claims description 76
- 102100031251 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Human genes 0.000 claims description 74
- 102100029115 Fumarylacetoacetase Human genes 0.000 claims description 74
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 74
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 73
- 108700040193 Adenylosuccinate lyases Proteins 0.000 claims description 73
- 108700040066 Argininosuccinate lyases Proteins 0.000 claims description 73
- 210000004027 cell Anatomy 0.000 claims description 73
- 102000015437 Uroporphyrinogen decarboxylase Human genes 0.000 claims description 72
- 108010064762 Uroporphyrinogen decarboxylase Proteins 0.000 claims description 72
- 101710189720 Porphobilinogen deaminase Proteins 0.000 claims description 71
- 101710170827 Porphobilinogen deaminase, chloroplastic Proteins 0.000 claims description 71
- 101710100896 Probable porphobilinogen deaminase Proteins 0.000 claims description 71
- 101001126842 Homo sapiens Protein O-glucosyltransferase 1 Proteins 0.000 claims description 70
- 230000035772 mutation Effects 0.000 claims description 69
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 claims description 69
- 102100032360 Alstrom syndrome protein 1 Human genes 0.000 claims description 66
- 101000797795 Homo sapiens Alstrom syndrome protein 1 Proteins 0.000 claims description 64
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims description 64
- 108010053763 Pyruvate Carboxylase Proteins 0.000 claims description 63
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 claims description 63
- 101710200421 Low density lipoprotein receptor adapter protein 1 Proteins 0.000 claims description 61
- 108010058065 Aminomethyltransferase Proteins 0.000 claims description 60
- 101000914673 Homo sapiens Fanconi anemia group A protein Proteins 0.000 claims description 60
- 101000918487 Homo sapiens Fumarylacetoacetase Proteins 0.000 claims description 60
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 58
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 58
- 101150065637 Hfe gene Proteins 0.000 claims description 58
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 claims description 57
- 108700022944 Hemochromatosis Proteins 0.000 claims description 57
- 108010086524 Hepatocyte Nuclear Factor 4 Proteins 0.000 claims description 57
- 108010021582 Glucokinase Proteins 0.000 claims description 56
- 102000030595 Glucokinase Human genes 0.000 claims description 56
- 101710115512 Nuclear receptor coactivator 5 Proteins 0.000 claims description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 55
- 102100031180 Hereditary hemochromatosis protein Human genes 0.000 claims description 54
- 102000036693 Thrombopoietin Human genes 0.000 claims description 54
- 108010041111 Thrombopoietin Proteins 0.000 claims description 54
- 108010013792 Isovaleryl-CoA Dehydrogenase Proteins 0.000 claims description 53
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 52
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 52
- 229940100601 interleukin-6 Drugs 0.000 claims description 52
- 101710146191 Ceramide synthase 2 Proteins 0.000 claims description 51
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 claims description 51
- 208000011580 syndromic disease Diseases 0.000 claims description 51
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims description 51
- 108050003337 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Proteins 0.000 claims description 50
- -1 PIK3RAP1 Proteins 0.000 claims description 49
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 45
- 201000010099 disease Diseases 0.000 claims description 37
- 102100036291 Galactose-1-phosphate uridylyltransferase Human genes 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 206010012601 diabetes mellitus Diseases 0.000 claims description 33
- 102100029237 Hexokinase-4 Human genes 0.000 claims description 32
- 102000011936 Apolipoprotein A-V Human genes 0.000 claims description 30
- 108010061118 Apolipoprotein A-V Proteins 0.000 claims description 30
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 claims description 30
- 108700028369 Alleles Proteins 0.000 claims description 29
- 101150087263 Cers2 gene Proteins 0.000 claims description 29
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 claims description 29
- 108010015181 PPAR delta Proteins 0.000 claims description 29
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 claims description 28
- 201000000357 hemochromatosis type 2B Diseases 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 108091092195 Intron Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 208000035544 Nonketotic hyperglycinaemia Diseases 0.000 claims description 20
- 201000011205 glycine encephalopathy Diseases 0.000 claims description 20
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 18
- 208000005452 Acute intermittent porphyria Diseases 0.000 claims description 17
- 208000027472 Galactosemias Diseases 0.000 claims description 17
- 206010036182 Porphyria acute Diseases 0.000 claims description 17
- 208000006227 SHORT syndrome Diseases 0.000 claims description 17
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 17
- 208000010583 Dowling-Degos disease 4 Diseases 0.000 claims description 16
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 16
- 101710142822 Hereditary hemochromatosis protein Proteins 0.000 claims description 16
- 208000000420 Isovaleric acidemia Diseases 0.000 claims description 16
- 208000018839 Wilson disease Diseases 0.000 claims description 16
- 108700036927 isovaleric Acidemia Proteins 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 16
- 206010043554 thrombocytopenia Diseases 0.000 claims description 16
- 206010010099 Combined immunodeficiency Diseases 0.000 claims description 15
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 206010020606 Hyperchylomicronaemia Diseases 0.000 claims description 14
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 claims description 14
- 108010022687 fumarylacetoacetase Proteins 0.000 claims description 14
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 14
- 230000001105 regulatory effect Effects 0.000 claims description 14
- 235000000346 sugar Nutrition 0.000 claims description 14
- 108091006112 ATPases Proteins 0.000 claims description 13
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims description 13
- 102000007592 Apolipoproteins Human genes 0.000 claims description 13
- 108010071619 Apolipoproteins Proteins 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 13
- 230000002440 hepatic effect Effects 0.000 claims description 13
- 230000037356 lipid metabolism Effects 0.000 claims description 13
- 208000008190 Agammaglobulinemia Diseases 0.000 claims description 12
- 101710191958 Amino-acid acetyltransferase Proteins 0.000 claims description 12
- 108091004554 Copper Transport Proteins Proteins 0.000 claims description 12
- 102000020856 Copper Transport Proteins Human genes 0.000 claims description 12
- 206010019629 Hepatic adenoma Diseases 0.000 claims description 12
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 12
- 108091027974 Mature messenger RNA Proteins 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 208000006454 hepatitis Diseases 0.000 claims description 12
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 12
- 201000007851 type 1 diabetes mellitus 20 Diseases 0.000 claims description 12
- 208000012789 Deafness-enamel hypoplasia-nail defects syndrome Diseases 0.000 claims description 11
- 208000013016 Hypoglycemia Diseases 0.000 claims description 11
- 206010022489 Insulin Resistance Diseases 0.000 claims description 11
- 108091007960 PI3Ks Proteins 0.000 claims description 11
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 11
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 11
- 101710112761 Protein O-glucosyltransferase 1 Proteins 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 208000014018 liver neoplasm Diseases 0.000 claims description 11
- 238000003786 synthesis reaction Methods 0.000 claims description 11
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 10
- 206010010356 Congenital anomaly Diseases 0.000 claims description 10
- 208000004930 Fatty Liver Diseases 0.000 claims description 10
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 10
- 241000097929 Porphyria Species 0.000 claims description 10
- 208000010642 Porphyrias Diseases 0.000 claims description 10
- 239000003613 bile acid Substances 0.000 claims description 10
- 201000008230 cutaneous porphyria Diseases 0.000 claims description 10
- 201000007270 liver cancer Diseases 0.000 claims description 10
- 201000011296 tyrosinemia Diseases 0.000 claims description 10
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims description 9
- 201000009628 adenosine deaminase deficiency Diseases 0.000 claims description 9
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims description 9
- 208000032001 Tyrosinemia type 1 Diseases 0.000 claims description 8
- 201000003554 argininosuccinic aciduria Diseases 0.000 claims description 8
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 8
- 238000010255 intramuscular injection Methods 0.000 claims description 8
- 239000007927 intramuscular injection Substances 0.000 claims description 8
- 239000007928 intraperitoneal injection Substances 0.000 claims description 8
- 238000010253 intravenous injection Methods 0.000 claims description 8
- 208000018191 liver inflammation Diseases 0.000 claims description 8
- 208000003013 permanent neonatal diabetes mellitus Diseases 0.000 claims description 8
- 238000010254 subcutaneous injection Methods 0.000 claims description 8
- 239000007929 subcutaneous injection Substances 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 7
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 7
- 101710088194 Dehydrogenase Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 101710090046 Galactose-1-phosphate uridylyltransferase Proteins 0.000 claims description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 230000036961 partial effect Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 claims description 5
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 claims description 5
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 claims description 5
- 102000009824 Hepatocyte Nuclear Factor 1-alpha Human genes 0.000 claims description 5
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims description 5
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 230000000670 limiting effect Effects 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 230000001594 aberrant effect Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- UYVZIWWBJMYRCD-ZMHDXICWSA-N isovaleryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 UYVZIWWBJMYRCD-ZMHDXICWSA-N 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 claims 29
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 claims 29
- 102100034195 Thrombopoietin Human genes 0.000 claims 29
- 101710155270 Glycerate 2-kinase Proteins 0.000 claims 28
- 101001021379 Homo sapiens Galactose-1-phosphate uridylyltransferase Proteins 0.000 claims 28
- 101000923835 Homo sapiens Low density lipoprotein receptor adapter protein 1 Proteins 0.000 claims 28
- 101000598921 Homo sapiens Orexin Proteins 0.000 claims 28
- 101001123245 Homo sapiens Protoporphyrinogen oxidase Proteins 0.000 claims 28
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 claims 28
- 101000766332 Homo sapiens Tribbles homolog 1 Proteins 0.000 claims 28
- 101000910482 Homo sapiens Uroporphyrinogen decarboxylase Proteins 0.000 claims 28
- 101710201965 Isovaleryl-CoA dehydrogenase, mitochondrial Proteins 0.000 claims 28
- 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 claims 28
- 102100029028 Protoporphyrinogen oxidase Human genes 0.000 claims 28
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims 28
- 102100026387 Tribbles homolog 1 Human genes 0.000 claims 28
- 102100024118 Uroporphyrinogen decarboxylase Human genes 0.000 claims 28
- 101000974352 Homo sapiens Nuclear receptor coactivator 5 Proteins 0.000 claims 27
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 claims 27
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 claims 27
- 101001129184 Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 Proteins 0.000 claims 24
- 102100036664 Adenosine deaminase Human genes 0.000 claims 21
- 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 claims 21
- 101000887804 Homo sapiens Aminomethyltransferase, mitochondrial Proteins 0.000 claims 21
- 102000048988 Hemochromatosis Human genes 0.000 claims 19
- 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 claims 4
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 claims 4
- 208000012130 acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 4
- 102000009042 Argininosuccinate Lyase Human genes 0.000 claims 3
- 102000015902 Hepatocyte nuclear factor 4-alpha Human genes 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 2
- 101000843904 Arabidopsis thaliana Bifunctional phosphatase IMPL2, chloroplastic Proteins 0.000 claims 1
- 101100352374 Oryza sativa subsp. japonica PLA3 gene Proteins 0.000 claims 1
- 108010060499 acharan sulfate lyase 1 Proteins 0.000 claims 1
- 238000006356 dehydrogenation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 108010058532 UTP-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 79
- 102000006321 UTP-hexose-1-phosphate uridylyltransferase Human genes 0.000 description 79
- 235000018102 proteins Nutrition 0.000 description 61
- 230000014759 maintenance of location Effects 0.000 description 55
- 208000024891 symptom Diseases 0.000 description 39
- 108700024394 Exon Proteins 0.000 description 36
- 102100040768 60S ribosomal protein L32 Human genes 0.000 description 15
- 101000672453 Homo sapiens 60S ribosomal protein L32 Proteins 0.000 description 15
- 230000008859 change Effects 0.000 description 15
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 description 13
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 description 13
- 208000027969 immunodeficiency 36 Diseases 0.000 description 11
- 101710183496 3 beta-hydroxysteroid dehydrogenase type 7 Proteins 0.000 description 10
- 208000008425 Protein deficiency Diseases 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 210000004940 nucleus Anatomy 0.000 description 10
- 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 7
- 201000000391 hemochromatosis type 1 Diseases 0.000 description 7
- 102100027211 Albumin Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 208000009642 Severe combined immunodeficiency due to adenosine deaminase deficiency Diseases 0.000 description 6
- 206010072656 Very long-chain acyl-coenzyme A dehydrogenase deficiency Diseases 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 description 6
- 206010068783 Alstroem syndrome Diseases 0.000 description 5
- 201000005932 Alstrom Syndrome Diseases 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 5
- 208000029140 neonatal diabetes Diseases 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 208000018565 Hemochromatosis Diseases 0.000 description 4
- 101000930800 Homo sapiens HLA class II histocompatibility antigen, DQ beta 1 chain Proteins 0.000 description 4
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 4
- 101000616523 Homo sapiens SH2B adapter protein 3 Proteins 0.000 description 4
- 102100023915 Insulin Human genes 0.000 description 4
- 208000036626 Mental retardation Diseases 0.000 description 4
- 102100021778 SH2B adapter protein 3 Human genes 0.000 description 4
- 206010072659 Type 3 diabetes mellitus Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 201000002125 familial hyperinsulinemic hypoglycemia 3 Diseases 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 101150112159 hhf3 gene Proteins 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005976 liver dysfunction Effects 0.000 description 4
- 201000001247 maturity-onset diabetes of the young type 2 Diseases 0.000 description 4
- 201000001250 maturity-onset diabetes of the young type 3 Diseases 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 101150080366 ACADVL gene Proteins 0.000 description 3
- 101150091481 ATP7 gene Proteins 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 101150003775 HNF1A gene Proteins 0.000 description 3
- 101001120470 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Peptidoglycan-associated lipoprotein Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 101150005926 Pc gene Proteins 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 208000035415 Reinfection Diseases 0.000 description 3
- 101150106192 Urod gene Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- KDZOASGQNOPSCU-UHFFFAOYSA-N argininosuccinate Chemical compound OC(=O)C(N)CCCN=C(N)NC(C(O)=O)CC(O)=O KDZOASGQNOPSCU-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000037434 nonsense mutation Effects 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 101150074566 ppox gene Proteins 0.000 description 3
- 101150005161 ALMS1 gene Proteins 0.000 description 2
- 101150103672 AMT gene Proteins 0.000 description 2
- 101150077253 APOA5 gene Proteins 0.000 description 2
- 101150075644 ATP7B gene Proteins 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 102100036774 Afamin Human genes 0.000 description 2
- 101710198494 Alstrom syndrome protein 1 Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010011891 Deafness neurosensory Diseases 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 101150094145 FAH gene Proteins 0.000 description 2
- 101150102398 Galt gene Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 101150043052 Hamp gene Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 101150034920 Hmbs gene Proteins 0.000 description 2
- 101100162491 Homo sapiens ALMS1 gene Proteins 0.000 description 2
- 101100244213 Homo sapiens PNPLA3 gene Proteins 0.000 description 2
- 206010058359 Hypogonadism Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010065973 Iron Overload Diseases 0.000 description 2
- 101150095117 Ivd gene Proteins 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 208000007379 Muscle Hypotonia Diseases 0.000 description 2
- 101150043140 NCOA5 gene Proteins 0.000 description 2
- 101150046396 PIK3R1 gene Proteins 0.000 description 2
- 101150102309 POGLUT1 gene Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 208000026980 Renal tubular disease Diseases 0.000 description 2
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 2
- 101150116986 THPO gene Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 101150027964 ada gene Proteins 0.000 description 2
- 108010090535 alpha-albumin Proteins 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 101150036914 gck gene Proteins 0.000 description 2
- 108010014977 glycine cleavage system Proteins 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 231100000845 liver adenoma Toxicity 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102220566028 3 beta-hydroxysteroid dehydrogenase type 7_G19S_mutation Human genes 0.000 description 1
- MOTVYDVWODTRDF-UHFFFAOYSA-N 3-[7,12,17-tris(2-carboxyethyl)-3,8,13,18-tetrakis(carboxymethyl)-21,22-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CC(O)=O)C(=CC=3C(=C(CC(O)=O)C(=C4)N=3)CCC(O)=O)N2)CCC(O)=O)=C(CC(O)=O)C(CCC(O)=O)=C1C=C1C(CC(O)=O)=C(CCC(=O)O)C4=N1 MOTVYDVWODTRDF-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 108700016481 Acute Hepatic Porphyria Proteins 0.000 description 1
- 208000003914 Acute hepatic porphyria Diseases 0.000 description 1
- 108091006986 Amt proteins Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 102100022344 Cardiac phospholamban Human genes 0.000 description 1
- 206010007617 Cardio-respiratory arrest Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 101100520033 Dictyostelium discoideum pikC gene Proteins 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 206010061958 Food Intolerance Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 102300052097 Hepatocyte nuclear factor 4-alpha isoform HNF4-Alpha-2 Human genes 0.000 description 1
- 102220561817 Hereditary hemochromatosis protein_S65C_mutation Human genes 0.000 description 1
- 101000620629 Homo sapiens Cardiac phospholamban Proteins 0.000 description 1
- 101600072310 Homo sapiens Hepatocyte nuclear factor 4-alpha (isoform HNF4-Alpha-2) Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101100482208 Homo sapiens TRIB1 gene Proteins 0.000 description 1
- 101000835086 Homo sapiens Transferrin receptor protein 2 Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023138 Jaundice neonatal Diseases 0.000 description 1
- 206010062310 Joint hyperextension Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000035450 Malformed Nails Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 208000036769 Mild mental retardation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 201000006346 Neonatal Jaundice Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 206010052649 Primary hypogonadism Diseases 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150016990 TRIB1 gene Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010044041 Tooth hypoplasia Diseases 0.000 description 1
- 102100026143 Transferrin receptor protein 2 Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 208000025261 autosomal dominant disease Diseases 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000030498 cytoplasmic translation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000002268 dental enamel hypoplasia Diseases 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000005221 enamel hypoplasia Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 201000003585 eunuchism Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 201000006321 fundus dystrophy Diseases 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 201000000354 hemochromatosis type 3 Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000033552 hepatic porphyria Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 1
- 208000037106 male hypogonadism Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 101150075122 ppard gene Proteins 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000016685 primary ovarian failure Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 102200075063 rs104894696 Human genes 0.000 description 1
- 102220236480 rs1131692207 Human genes 0.000 description 1
- 102200101053 rs121965073 Human genes 0.000 description 1
- 102200129027 rs2076213 Human genes 0.000 description 1
- 102200092203 rs3135506 Human genes 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267238P | 2015-12-14 | 2015-12-14 | |
| US62/267,238 | 2015-12-14 | ||
| US201662319015P | 2016-04-06 | 2016-04-06 | |
| US62/319,015 | 2016-04-06 | ||
| PCT/US2016/066564 WO2017106283A1 (en) | 2015-12-14 | 2016-12-14 | Compositions and methods for treatment of liver diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019500345A true JP2019500345A (ja) | 2019-01-10 |
| JP2019500345A5 JP2019500345A5 (enrdf_load_stackoverflow) | 2020-01-30 |
Family
ID=59057460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529229A Pending JP2019500345A (ja) | 2015-12-14 | 2016-12-14 | 肝臓病の処置のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3389672A4 (enrdf_load_stackoverflow) |
| JP (1) | JP2019500345A (enrdf_load_stackoverflow) |
| CA (1) | CA3005090A1 (enrdf_load_stackoverflow) |
| WO (1) | WO2017106283A1 (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022544702A (ja) * | 2019-08-19 | 2022-10-20 | ストーク セラピューティクス，インク． | スプライシングおよびタンパク質発現を調節するための組成物および方法 |
| JP2023534557A (ja) * | 2020-07-23 | 2023-08-09 | エフ． ホフマン－ラ ロシュ アーゲー | Ｒｎａ結合タンパク質部位を標的とするオリゴヌクレオチド |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| AU2015327836B2 (en) | 2014-10-03 | 2021-07-01 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| AU2016334804B2 (en) | 2015-10-09 | 2022-03-31 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| EP3933041B1 (en) | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant retardation |
| JP7094963B2 (ja) | 2017-01-23 | 2022-07-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｈｓｄ１７ｂ１３バリアントおよびその使用 |
| CA3059348A1 (en) | 2017-04-11 | 2018-10-18 | Regeneron Pharmaceuticals, Inc. | Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family |
| CA3073515A1 (en) | 2017-08-25 | 2019-02-28 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
| EP3461837A1 (en) * | 2017-09-28 | 2019-04-03 | Secarna Pharmaceuticals GmbH & Co. KG | Inhibitor inhibiting the expression of pprx1 |
| AU2018348195B2 (en) | 2017-10-11 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
| SMT202500127T1 (it) | 2017-10-23 | 2025-05-12 | Stoke Therapeutics Inc | Oligomeri antisenso per il trattamento di malattie e condizioni basate sul decadimento dell’rna mediato da un nonsenso |
| WO2019161105A1 (en) * | 2018-02-14 | 2019-08-22 | Deep Genomics Incorporated | Oligonucleotide therapy for wilson disease |
| MX2020008581A (es) * | 2018-02-21 | 2020-09-21 | Bristol Myers Squibb Co | Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos. |
| MX2020009812A (es) | 2018-03-21 | 2021-01-08 | Regeneron Pharma | COMPOSICIONES DE ARNI DE 17ß-HIDROXIESTEROIDE DESHIDROGENASA TIPO 13 (HSD17B13) Y MÉTODOS DE USO DE LAS MISMAS. |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| TWI869213B (zh) | 2018-09-19 | 2025-01-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
| CN111849968A (zh) * | 2019-04-30 | 2020-10-30 | 中美瑞康核酸技术(南通)研究院有限公司 | 寡核苷酸分子及其在急性间歇性卟啉症治疗中的应用 |
| KR20220070206A (ko) * | 2019-09-20 | 2022-05-30 | 락티젠 세러퓨틱스 | 혈소판 감소증 치료용 핵산 분자 및 그의 이용 |
| WO2021074772A1 (en) * | 2019-10-14 | 2021-04-22 | Astrazeneca Ab | Modulators of pnpla3 expression |
| EP4069255A4 (en) * | 2019-12-04 | 2024-02-21 | Pai, Athma A. | IDENTIFICATION OF NON-PRODUCTIVE SPLICE JOINTS |
| TW202208627A (zh) | 2020-05-11 | 2022-03-01 | 美商斯托克治療公司 | 用於病症及疾病之治療的opa1反義寡聚物 |
| WO2021231698A1 (en) * | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
| WO2022109030A1 (en) * | 2020-11-17 | 2022-05-27 | Skyhawk Therapeutics, Inc. | Rna-targeting splicing modifiers for treatment of pnpla3-associated conditions and diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140128449A1 (en) * | 2011-04-07 | 2014-05-08 | The Board Of Regents Of The University Of Texas System | Oligonucleotide modulation of splicing |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866042A (en) | 1987-11-18 | 1989-09-12 | Neuwelt Edward A | Method for the delivery of genetic material across the blood brain barrier |
| US6294520B1 (en) | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| CA2145535C (en) | 1992-09-25 | 2007-07-17 | Axel Kahn | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
| US5656612A (en) | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| FR2727867B1 (fr) | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
| US6936589B2 (en) | 2001-09-28 | 2005-08-30 | Albert T. Naito | Parenteral delivery systems |
| US7291461B2 (en) * | 2002-06-21 | 2007-11-06 | Ptc Therapeutics, Inc. | Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay |
| EP1874958B1 (en) * | 2005-04-01 | 2019-03-27 | University of Florida Research Foundation, Incorporated | Biomarkers of liver injury |
| WO2007047913A2 (en) | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| MX361732B (es) | 2009-06-17 | 2018-12-14 | Cold Spring Harbor Laboratory | Composiciones y metodos para la modulacion de division de smn2 en un sujeto. |
| US8853377B2 (en) * | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| EP3690048A1 (en) | 2013-09-04 | 2020-08-05 | Cold Spring Harbor Laboratory | Reducing nonsense-mediated mrna decay |
-
2016
- 2016-12-14 CA CA3005090A patent/CA3005090A1/en active Pending
- 2016-12-14 EP EP16876543.6A patent/EP3389672A4/en not_active Withdrawn
- 2016-12-14 WO PCT/US2016/066564 patent/WO2017106283A1/en active Application Filing
- 2016-12-14 JP JP2018529229A patent/JP2019500345A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140128449A1 (en) * | 2011-04-07 | 2014-05-08 | The Board Of Regents Of The University Of Texas System | Oligonucleotide modulation of splicing |
Non-Patent Citations (9)
| Title |
|---|
| LLEWELLYN, D. H. ET AL., J MED GENET, vol. 33, JPN6020050338, 1996, pages 437 - 8, ISSN: 0004416760 * |
| MARTINEZ DI MONTEMUROS, F. ET AL., BLOOD CELL MOL DIS, vol. 27, JPN6020050337, 2001, pages 961 - 70, ISSN: 0004416759 * |
| MUSTAJOKI, S. ET AL., HUM GENET, vol. 102, JPN6020050336, 1998, pages 541 - 8, ISSN: 0004416758 * |
| PNAS, vol. 93, JPN6020044617, 1996, pages 12840 - 12844, ISSN: 0004416766 * |
| PRICE, L. ET AL., NEUROMUSCUL DISORD, vol. 22, JPN6020050344, 2012, pages 862, ISSN: 0004416764 * |
| RIVERA-BARAHONA, A. ET AL., PLOS ONE, vol. 10, JPN6020050343, April 2015 (2015-04-01), pages 0122966 - 1, ISSN: 0004416763 * |
| ROBREAU-FRAOLINI, A. M. ET AL., HUM GENET, vol. 107, JPN6020050342, 2000, pages 150 - 9, ISSN: 0004416762 * |
| VAN BLITTERSWIJK, M. ET AL., AMYOTROPH LATERAL SCLER FRONTOTEMPORAL DEGENER, vol. 165, JPN6020050346, October 2015 (2015-10-01), pages 9, ISSN: 0004416765 * |
| 五十嵐正樹, 外9名, 臨床血液, vol. 45, JPN6020050339, 2004, pages 562 - 7, ISSN: 0004416761 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022544702A (ja) * | 2019-08-19 | 2022-10-20 | ストーク セラピューティクス，インク． | スプライシングおよびタンパク質発現を調節するための組成物および方法 |
| JP2023534557A (ja) * | 2020-07-23 | 2023-08-09 | エフ． ホフマン－ラ ロシュ アーゲー | Ｒｎａ結合タンパク質部位を標的とするオリゴヌクレオチド |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017106283A1 (en) | 2017-06-22 |
| EP3389672A1 (en) | 2018-10-24 |
| CA3005090A1 (en) | 2017-06-22 |
| EP3389672A4 (en) | 2019-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500345A (ja) | 肝臓病の処置のための組成物および方法 | |
| JP7420679B2 (ja) | 状態および疾患の処置のためのアンチセンスオリゴマー | |
| JP7049247B2 (ja) | 腎臓病の処置のための組成物と方法 | |
| EP3390636B1 (en) | Antisense oligomers for treatment of dravet syndrome | |
| JP7054675B2 (ja) | 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法 | |
| JP7051683B2 (ja) | 結節性硬化症の処置のためのアンチセンスオリゴマー | |
| JP2022106803A (ja) | アラジール症候群の処置のためのアンチセンスオリゴマー | |
| KR20220084437A (ko) | 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법 | |
| JP2022544702A (ja) | スプライシングおよびタンパク質発現を調節するための組成物および方法 | |
| JP2018538287A (ja) | 多発性嚢胞腎の処置のためのアンチセンスオリゴマー | |
| TWI769197B (zh) | 用於治療多囊腎病之組成物 | |
| CN115867657A (zh) | 用于治疗疾患和疾病的opa1反义寡聚物 | |
| US20240254488A1 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| US20230287427A1 (en) | Inhibition of lncExACT1 to Treat Heart Disease | |
| WO2023235509A2 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| CN117413061A (zh) | 用于治疗与多囊蛋白表达相关的疾患和疾病的组合物 | |
| US20250283086A1 (en) | Compositions and methods for treatment of kidney disease | |
| WO2024254639A1 (en) | Compositions and methods for treatment of kidney disease | |
| WO2023235915A1 (en) | Compositions and methods for treatment of monogenic neurodevelopmental disorder | |
| WO2025111653A1 (en) | Improved compositions and methods for treatment of monogenic neurodevelopmental disorders | |
| HK1262955B (en) | Antisense oligomers for treatment of dravet syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180806 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20190531 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200819 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200819 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201225 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210324 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210625 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211124 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220420 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220524 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221004 |